Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Real World Study of Anlotinib for Patients With Advanced Medullary Thyroid Carcinoma

NCT05830500 is registered in ClinicalTrials.gov with Chia Tai Tianqing Pharmaceutical Group Co., Ltd. as lead sponsor.

NCT NCT05830500
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05830500 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Real World Study of Anlotinib for Patients With Advanced Medullary Thyroid Carcinoma
Lead sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase
Phase 4
Overall status
Recruiting
Start date
June 19, 2023
Completion date
December 31, 2028
Enrollment
360 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

medullary thyroid cancer